[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stomach-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stomach-gastric-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641271","non-operative-management-and-following-immunotherapy-for-colorectal-cancer-and-other-gi-cancers-100641271",false,"NCT07656740","Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers","Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers (NOMIC Trial)","NOMIC","Inclusion Criteria:\n\n1. Retrospective Cohort Inclusion Criteria\n\n   * Pathologically confirmed gastrointestinal malignancy determined as MSI-H\u002FdMMR or POLE mutation, and initially resectable.\n   * Completed prior immunotherapy.\n   * No evidence of distant metastasis.\n   * Managed with W\\&W, LE, endoscopic surgery, or radical operation after treatment.\n2. Prospective Cohort Inclusion Criteria\n\n   * Pathologically confirmed gastrointestinal malignancy determined as MSI-H\u002FdMMR or POLE mutation, and initially resectable.\n   * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n   * Immunotherapy status: naive, currently receiving, or completed treatment, and evaluated by the PKUCH-NOMIC research group as cCR\u002Fnear-cCR or Non-cCR (≤ ymrT2N0).\n   * No evidence of distant metastasis.\n   * Absence of emergencies requiring immediate surgery (e.g., hemorrhage, perforation, obstruction).\n\nExclusion Criteria:\n\n* Recurrent gastrointestinal tumors.Initial presence of unresectable distant metastases.\n* Serum creatinine \\> 1.5 times upper limit of normal (ULN).\n* History of pelvic radiation therapy.Inability to tolerate MRI examinations.\n* History of other malignancies within the past 5 years with a survival rate significantly lower than the historical rectal cancer survival data of this center (except adequately treated basal cell carcinoma, cutaneous squamous cell carcinoma, small renal cell carcinoma, breast cancer, and papillary thyroid carcinoma).\n* Arterial thromboembolic events within the past 6 months (e.g., angina, myocardial infarction, transient ischemic attack \\[TIA\\], cerebral vascular accident \\[CVA\\]).\n* Prior receipt of other types of investigational anti-tumor therapies.\n* Pregnant or lactating women.\n* Concomitant diseases or mental health conditions that may interfere with study participation.","ALL",{"count":19,"type":20},50,"ESTIMATED","3 Years","OBSERVATIONAL","This is a single-center, bidirectional (retrospective and prospective) registry study aimed at evaluating the safety and efficacy of Non-Operative Management (NOM) and Organ-Preserving Functional Surgery (OPFS) in patients with mismatch repair-deficient\u002Fmicrosatellite instability-high (dMMR\u002FMSI-H) or POLE-mutated gastrointestinal (GI) cancers who received neoadjuvant immunotherapy.Patients achieving a clinical complete response (cCR) or near-cCR may undergo a \"Watch \\& Wait\" (W\\&W) strategy, while those with near-cCR or non-cCR ($\\\\le ymrT2N0$) may undergo local excision (LE) or endoscopic resection (ESD\u002FEMR). Patients undergoing radical operation (RO) will serve as the control cohort to compare oncological outcomes and safety data.",[25,26,27],"Gastrointestinal Cancer","Colorectal (Colon or Rectal) Cancer","Stomach (Gastric) Cancer",[29,30],"dMMR\u002FMSI-H","POLE-mutated","NOT_YET_RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":32,"type":20},{"date":38,"type":20},"2030-10-15",{"name":40,"class":41},"Peking University Cancer Hospital & Institute","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100630510","phase-3-progain-trial-in-gastric-cancer-surgery-100630510","NCT07488611","PROGAIN Trial in Gastric Cancer Surgery","The PROGAIN Trial : A Randomized Study of Protein-enriched Parenteral Nutrition on Nitrogen Balance and Recovery in Perioperative Gastric Cancer Surgery","PROGAIN","Inclusion Criteria:\n\n* Adults aged 19 years or older scheduled to undergo gastric cancer surgery. - Patients who have provided written informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Patients with uncontrolled severe systemic diseases (e.g., decompensated diabetes, cerebrovascular event within the last 6 months, sepsis, heart failure).\n* Patients who have received intravenous parenteral nutrition within 7 days prior to randomization.\n* Patients with severe metabolic abnormalities confirmed by preoperative laboratory tests, including but not limited to:\n\n  * Triglyceride \\> 400 mg\u002FdL\n  * AST or ALT \\> 3 x Upper Limit of Normal (ULN)\n  * Total Bilirubin \\> 3 x ULN\n  * Serum Creatinine \\> 2 x ULN\n  * HbA1c \\> 9.0%\n  * Potassium \\\u003C 3.0 mEq\u002FL or \\> 6.0 mEq\u002FL\n  * Calcium \\> 12.5 mg\u002FdL\n  * Sodium \\> 155 mmol\u002FL\n  * Magnesium \\> 3.0 mg\u002FdL\n* Patients deemed inappropriate for participation in this clinical trial by the investigator.","19 Years",{"count":53,"type":20},110,"INTERVENTIONAL",[56],"PHASE3","This randomized study will evaluate whether protein-enriched parenteral nutrition improves early postoperative recovery in patients undergoing gastrectomy for gastric cancer. Participants will be assigned to receive either protein-enriched parenteral nutrition or standard parenteral nutrition during the perioperative period. The primary outcome is nitrogen balance on postoperative day 5. Secondary outcomes include postoperative complications, recovery of oral intake, and short-term changes in nutritional status and body composition.",[27],[60,61,62,63,64,65,66],"Parenteral Nutrition","Gastrectomy","Nitrogen Balance","Protein enriched","Perioperative nutrition","Enhanced Recovery After Surgery","Stomach Neoplasms","RECRUITING","2026-05-16",{"date":70,"type":35},"2026-05-19",{"date":72,"type":35},"2026-02-13",{"date":74,"type":20},"2028-03",{"name":76,"class":41},"Soonchunhyang University Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":54,"phases":87,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100619216","phase-1-sl-28-for-advanced-solid-tumours-100619216","NCT07341737","SL-28 for Advanced Solid Tumours","A Phase 1\u002F2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n* Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study\n* Adult males and females ≥18 years of age at screening\n* Life expectancy of at least 3 months\n* Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)\n* Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular\u002Fbiomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate\n* Eligible tumor types include:\n* Head and neck squamous cell carcinoma\n* Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)\n* Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)\n* Genitourinary malignancies (bladder, renal cell, prostate cancer)\n* Gynecologic malignancies (ovarian, endometrial cancer)\n* Breast cancer and melanoma\n* Evaluable disease per RECIST v1.1\n* ECOG performance status 0-1 (or up to 2 at PI discretion)\n* Adequate organ function, defined as:\n* Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)\n* AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)\n* Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault) or eGFR ≥50 mL\u002Fmin (CKD-EPI)\n* Absolute neutrophil count ≥1,000\u002Fmm³\n* Platelet count ≥100,000\u002Fmm³\n* Hemoglobin ≥90 g\u002FL without transfusion within 2 weeks\n* Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation)\n\nFemale patients:\n\n-Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose\n\nMale patients:\n\n* Agreement not to donate sperm for 90 days post-dose\n* Agreement to use adequate contraception as applicable\n* Suitable venous access for blood sampling\n* Willingness and ability to comply with study procedures and protocol requirements\n\nExclusion Criteria:\n\n* Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)\n* NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG\n* QTcF \\>470 ms (females) or \\>450 ms (males)\n* Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy\n* Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing\n* Prior therapies within restricted timeframes:\n* Immune checkpoint inhibitors or biologics within 28 days\n* Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days\n* Unapproved investigational drugs within 5 half-lives\n* Nitrosoureas or mitomycin C within 6 weeks\n* Concurrent malignancy within 5 years, except specified low-risk cancers\n* Pregnancy or breastfeeding\n* Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection\n* Inability or unwillingness to comply with protocol procedures\n* History of anaphylaxis or significant allergy interfering with participation\n* Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months\n* Conditions affecting drug absorption, distribution, metabolism, or excretion\n* Receipt of live vaccines within 28 days prior to screening\n* Participation in another investigational study within 30 days prior to screening","18 Years",{"count":86,"type":20},60,[88,89],"PHASE1","PHASE2","Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.",[92,93,94,95,96,97,98,27,99,100,101,102,103,104,105,106,107,108],"Head & Neck Cancer","Pancreas Carcinoma","Pancreas Cancer, Metastatic","Lung Adenocarcinoma","Lung Cancer (NSCLC)","Lung Cancer (Non-Small Cell)","Esophageal Cancer","Liver Cancer","Intestinal Cancer","Bladder Cancer","Renal Cancer","Prostate Cancer","Melanoma (Skin Cancer)","Breast Cancer","Ovarian Cancer","Endometrial Cancer","Colorectal Cancer","2026-01-13",{"date":111,"type":35},"2026-01-15",{"date":113,"type":20},"2026-02-01",{"date":115,"type":20},"2027-03-01",{"name":117,"class":118},"Second Life Therapeutics","INDUSTRY"]